Glytec Appoints Chief Operating Officer

Glytec, developer of personalized digital therapeutics, has appointed Ed Furlong as chief operating officer (COO). Furlong joins the company during a period of growth and will assume a key leadership role in scaling commercial operations to meet evolving customer needs.
 
“We are thrilled to welcome Ed Furlong to our executive team,” said Glytec President and CEO Bob Leonard. “Ed’s background in helping companies expand and diversify while sustaining strong financial health is ideally suited to our strategic imperatives, especially at this crucial juncture when demand for our products and services is increasing exponentially.”
 
Furlong’s experience in operations and financial management spans more than 30 years, most recently as COO and chief financial officer at Kyruus, a leader in provider search and scheduling solutions for hospitals and health systems, where he was instrumental in shaping the business model, building the organization and increasing revenues elevenfold. Furlong previously served in a similar capacity at Exa Corporation, maker of engineering simulation and visualization software, where he directed the company’s initial public offering, raised private equity and mezzanine debt financing, and achieved consistent growth and profitability.
 
Earlier in his career, Furlong served as a senior executive in the investment services industry for both Fidelity Strategic Investments and UAM Investment Services, where he spearheaded a wide range of startups and turnarounds and participated on several corporate boards. Furlong has a bachelor of science degree in economics from The Wharton School at the University of Pennsylvania and a master of business administration from Harvard Business School.
 
“It is very exciting for me to join Glytec on the heels of a record year where software subscriptions grew by 70 percent,” said Furlong. “I am impressed by the company’s track record of demonstrating both substantive cost savings as well as improvements in patient outcomes. I believe there will soon be some shifts in the market as relate to diabetes care and medication optimization, and I am inspired to be part of a team that partners with healthcare organizations to facilitate real change.”
 
Glytec develops personalized digital therapeutics, enabling best practices for inpatient and outpatient insulin management. The company’s patented and U.S. Food and Drug Administration-cleared software-as-a-medical-device solutions improve the safety and health of people with diabetes and make insulin a more effective medication option for those unable to achieve their treatment goals. Glytec combines evidence-based decision support technologies with expert clinical services to optimize insulin therapies in the hospital and at home, leading to reductions in hypoglycemia and other complications as well as avoidable ED visits, hospitalizations, readmissions and drug waste. The company has offices in Waltham, Mass.; and Greenville, S.C.